They're all dogs. Stop wasting your time with fat people, and start investing in real Bio's.
Nope ARNA's Belviq.......Is the winner!
New & Novel......Not rehashed generic combo drugs! Which are all Contrave & Qsymia are!
Buy low, sell high. You can get into OREX right now cheaper than insider acting as CEO right now who bought 50,000 shares.
Takeda's Director of Obesity Marketing Katie Andino told MM&M in a phone interview that the drugmaker will be taking a unique approach to courting all three parties. Although Andino could not discuss specifics until Contrave (naltrexone and bupropion) hits the marketplace, the brand already has experience with speaking to consumers differently, as seen by the tone and all-out approach Orexigen used when recruiting patients for its clinical trials.
In terms of commercial outreach, Andino said Takeda will be focusing on patients “who are ready to go on Contrave, [and] are in the right frame of mind” to pair a chronic medication with lifestyle changes that include an activity regimen and diet modification. These same add-ons are essential components for success with Belviq and Qsymia, but Takeda indicates its approach will add a new voice to the weight-loss conversation.
The professional push will include samples, speakers and 900 Takeda sales representatives, some of whom will be making only Contrave-focused visits, while others will be able to talk about Contrave as well as Takeda's diabetes medications. Because of the overlap between diabetes and obese patients—obesity can put patients at risk for diabetes—the firm has an opportunity to build on relationships they already have with physicians such as endocrinologists. Sales reps will also be addressing OB/GYNs, cardiologists and primary care physicians, and Takeda's payer group will be talking about the drug with insurers.